Category: Uncategorized - Page 67 - Start Medical Product Development

New technology successfully monitors cancer progression at the cellular level

July 17, 2025

Sensome, the pioneer of microsensing technology for real-time, in situ tissue analysis, today announced the publication of a study in Science Advances unveiling an innovative methodology using its technology to noninvasively monitor cell spatiotemporal dynamics involved in cancer progression in a real-time and label-free manner, which can provide new insights for cancer diagnosis and treatment.

Global study shows longer brain scans lower research costs, provide more accurate predictions

July 17, 2025

Artificial intelligence (AI) models trained on large datasets are increasingly seen as the key to unlocking personalized treatments for brain disorders. An important bottleneck for scaling AI is the cost of data collection. This raises a fundamental dilemma: is it more cost-effective to scan more people for a short time, or fewer people for longer?

AI can accelerate search for more effective Alzheimer’s medicines by streamlining clinical trials

July 17, 2025

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients with early-stage, slow-progressing mild cognitive impairment—a condition that can progress to Alzheimer’s.

Researchers develop novel antibody-RNA therapy for resistant cancers

July 17, 2025

A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models, according to a study reported in Science Translational Medicine.

Oncomine Dx Express Test Gains FDA Approval, Expanding Thermo Fisher’s Precision Oncology Portfolio

July 17, 2025

The FDA approval of Thermo Fisher’s Oncomine Dx Express Test marks a key advancement in precision oncology, enabling fast, accurate detection of EGFR exon 20 insertion mutations and guiding NSCLC patients to targeted treatments like ZEGFROVY.

Olympus Launches EU-ME3 Ultrasound Processor in U.S. for Advanced GI and Pulmonary Disease Detection

July 17, 2025

Next-Generation Platform Enhances Endoscopic Ultrasound Imaging to Support More Accurate and Efficient Diagnoses

Piccolo Medical, Inc. Receives FDA Clearance for 2nd Generation SmartPICC® technology

July 16, 2025

SAN FRANCISCO, July 16, 2025 /PRNewswire/ — Piccolo Medical, Inc. (Piccolo), a leading innovator in vascular access technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next-generation SmartPICC® Stylet and PM2+™ System. This significant achievement marks a major leap forward in safe, efficient, and cost-effective peripherally inserted central catheter (PICC) placement, offering enhanced benefits for both patients and healthcare providers.

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(k) clearance

July 16, 2025

CHARLOTTESVILLE, Va., July 16, 2025 /PRNewswire/ — RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or catheter placement.

Arthrex NanoScope™ System Receives Pediatric Clearance for Orthopedic, Laparoscopic Procedures

July 16, 2025

NAPLES, Fla., July 16, 2025 /PRNewswire/ — Arthrex, a global leader in minimally invasive surgical technology, announced that it has received U.S. Food and Drug Administration (FDA) clearance to use the Arthrex NanoScope™ operative arthroscopy system for pediatric orthopedics and laparoscopy.

Overture Orthopaedics Announces Full Commercial Launch of the OvertureTi Knee Resurfacing System® to Treat Early Osteoarthritis and Cartilage Defects

July 16, 2025

IRVINE, Calif., July 16, 2025 /PRNewswire/ — Overture Orthopaedics, a privately held U.S.-based medical device company providing surgeons with innovative joint preservation solutions in sports medicine and orthopaedic surgery, announced the full U.S. commercial launch of its OvertureTi Knee Resurfacing System. These implants were designed with sizing options that allow the surgeon to replace only the diseased or damaged region of the joint while preserving healthy surrounding cartilage and meniscus. The procedure is referred to as Focalplasty®.

Blog

- Uncategorized

New technology successfully monitors cancer progression at the cellular level

Global study shows longer brain scans lower research costs, provide more accurate predictions

AI can accelerate search for more effective Alzheimer’s medicines by streamlining clinical trials

Researchers develop novel antibody-RNA therapy for resistant cancers

Oncomine Dx Express Test Gains FDA Approval, Expanding Thermo Fisher’s Precision Oncology Portfolio

Olympus Launches EU-ME3 Ultrasound Processor in U.S. for Advanced GI and Pulmonary Disease Detection

Piccolo Medical, Inc. Receives FDA Clearance for 2nd Generation SmartPICC® technology

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(k) clearance

Arthrex NanoScope™ System Receives Pediatric Clearance for Orthopedic, Laparoscopic Procedures

Overture Orthopaedics Announces Full Commercial Launch of the OvertureTi Knee Resurfacing System® to Treat Early Osteoarthritis and Cartilage Defects